tetano
Editor, Senior Moderator
Shock
. 2020 Dec 29;Publish Ahead of Print.
doi: 10.1097/SHK.0000000000001680. Online ahead of print.
A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy
Julie Goswami[SUP] 1 [/SUP], Taleen A MacArthur, Meera Sridharan, Rajiv K Pruthi, Robert D McBane 2nd, Thomas E Witzig, Myung S Park
Affiliations
Abstract
There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a significant coagulopathy, a phenomenon termed "COVID-19 associated coagulopathy". COVID-19 has been associated with increased rates of both venous and arterial thromboembolic events, a source of significant morbidity and mortality in this disease. Further evidence suggests a link between the inflammatory response and coagulopathy associated with COVID-19. This presents a unique set of challenges for diagnosis, prevention, and treatment of thrombotic complications. In this review, we summarize and discuss the current literature on laboratory coagulation disruptions associated with COVID-19 and the clinical effects of thromboembolic events including pulmonary embolism (PE), deep vein thrombosis (DVT), peripheral arterial thrombosis, and acute ischemic stroke in COVID-19. Endothelial injury and augmented innate immune response are implicated in the development of diffuse macro- and microvascular thrombosis in COVID-19. The pathophysiology of COVID-19 associated coagulopathy is an important determinant of appropriate treatment and monitoring of these complications. We highlight the importance of diagnosis and management of dysregulated coagulation in COVID-19 in order to improve outcomes in COVID-19 patients with thromboembolic complications.
. 2020 Dec 29;Publish Ahead of Print.
doi: 10.1097/SHK.0000000000001680. Online ahead of print.
A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy
Julie Goswami[SUP] 1 [/SUP], Taleen A MacArthur, Meera Sridharan, Rajiv K Pruthi, Robert D McBane 2nd, Thomas E Witzig, Myung S Park
Affiliations
- PMID: 33378321
- DOI: 10.1097/SHK.0000000000001680
Abstract
There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a significant coagulopathy, a phenomenon termed "COVID-19 associated coagulopathy". COVID-19 has been associated with increased rates of both venous and arterial thromboembolic events, a source of significant morbidity and mortality in this disease. Further evidence suggests a link between the inflammatory response and coagulopathy associated with COVID-19. This presents a unique set of challenges for diagnosis, prevention, and treatment of thrombotic complications. In this review, we summarize and discuss the current literature on laboratory coagulation disruptions associated with COVID-19 and the clinical effects of thromboembolic events including pulmonary embolism (PE), deep vein thrombosis (DVT), peripheral arterial thrombosis, and acute ischemic stroke in COVID-19. Endothelial injury and augmented innate immune response are implicated in the development of diffuse macro- and microvascular thrombosis in COVID-19. The pathophysiology of COVID-19 associated coagulopathy is an important determinant of appropriate treatment and monitoring of these complications. We highlight the importance of diagnosis and management of dysregulated coagulation in COVID-19 in order to improve outcomes in COVID-19 patients with thromboembolic complications.